Ensysce Biosciences, Inc. (NASDAQ:ENSC) Short Interest Update

Ensysce Biosciences, Inc. (NASDAQ:ENSC) was the target of a significant decrease in short interest in March. As of March 15th, there was short interest totalling 22,000 shares, a decrease of 43.3% from the February 28th total of 38,800 shares. Based on an average daily volume of 53,400 shares, the short-interest ratio is currently 0.4 days. Currently, 1.8% of the company’s stock are sold short.

Ensysce Biosciences Stock Up 4.2 %

Shares of Ensysce Biosciences stock traded up $0.13 during trading on Friday, reaching $3.25. The company’s stock had a trading volume of 48,213 shares, compared to its average volume of 508,434. Ensysce Biosciences has a 1-year low of $2.12 and a 1-year high of $14.67. The company has a 50-day simple moving average of $5.46 and a two-hundred day simple moving average of $6.27. The company has a market cap of $4.57 million, a price-to-earnings ratio of -0.12 and a beta of 0.64.

Ensysce Biosciences (NASDAQ:ENSC) last issued its quarterly earnings results on Monday, March 10th. The company reported ($2.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.74) by ($0.16). The company had revenue of $1.30 million for the quarter, compared to analyst estimates of $0.25 million. Ensysce Biosciences had a negative net margin of 179.26% and a negative return on equity of 292.81%. As a group, analysts anticipate that Ensysce Biosciences will post -8.33 earnings per share for the current year.

Hedge Funds Weigh In On Ensysce Biosciences

A hedge fund recently bought a new stake in Ensysce Biosciences stock. Anson Funds Management LP purchased a new position in shares of Ensysce Biosciences, Inc. (NASDAQ:ENSC) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 983,518 shares of the company’s stock, valued at approximately $236,000. Anson Funds Management LP owned 11.15% of Ensysce Biosciences as of its most recent filing with the Securities and Exchange Commission. 5.63% of the stock is owned by hedge funds and other institutional investors.

About Ensysce Biosciences

Ensysce Biosciences, Inc, a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology.